192 related articles for article (PubMed ID: 27118251)
21. Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome.
Comim FV; Hardy K; Franks S
PLoS One; 2013; 8(11):e80416. PubMed ID: 24260388
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
23. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
Katsiki N; Hatzitolios AI
Curr Opin Obstet Gynecol; 2010 Dec; 22(6):466-76. PubMed ID: 20724929
[TBL] [Abstract][Full Text] [Related]
24. Enhanced thecal androgen production is prenatally programmed in an ovine model of polycystic ovary syndrome.
Hogg K; Young JM; Oliver EM; Souza CJ; McNeilly AS; Duncan WC
Endocrinology; 2012 Jan; 153(1):450-61. PubMed ID: 22087026
[TBL] [Abstract][Full Text] [Related]
25. Insulin sensitizers in polycystic ovary syndrome.
Pasquali R; Gambineri A
Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
[TBL] [Abstract][Full Text] [Related]
26. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
27. Valproate potentiates androgen biosynthesis in human ovarian theca cells.
Nelson-DeGrave VL; Wickenheisser JK; Cockrell JE; Wood JR; Legro RS; Strauss JF; McAllister JM
Endocrinology; 2004 Feb; 145(2):799-808. PubMed ID: 14576182
[TBL] [Abstract][Full Text] [Related]
28. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
29. Androgens and polycystic ovary syndrome.
Nisenblat V; Norman RJ
Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):224-31. PubMed ID: 19390322
[TBL] [Abstract][Full Text] [Related]
30. Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
Diamanti-Kandarakis E; Zapanti E
Ann N Y Acad Sci; 2000; 900():203-12. PubMed ID: 10818407
[TBL] [Abstract][Full Text] [Related]
31. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.
Hernández-Jiménez JL; Barrera D; Espinoza-Simón E; González J; Ortíz-Hernández R; Escobar L; Echeverría O; Torres-Ramírez N
Gynecol Endocrinol; 2022 Jan; 38(1):2-9. PubMed ID: 34787028
[TBL] [Abstract][Full Text] [Related]
32. Strategies to elucidate the mechanism of excessive theca cell androgen production in PCOS.
Strauss JF; Wood JR; Christenson LK; McAllister JM
Mol Cell Endocrinol; 2002 Jan; 186(2):183-8. PubMed ID: 11900894
[TBL] [Abstract][Full Text] [Related]
33. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome.
Arroyo P; Ho BS; Sau L; Kelley ST; Thackray VG
PLoS One; 2019; 14(9):e0223274. PubMed ID: 31568518
[TBL] [Abstract][Full Text] [Related]
34. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Tsilchorozidou T; Honour JW; Conway GS
J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.
Kempná P; Hofer G; Mullis PE; Flück CE
Mol Pharmacol; 2007 Mar; 71(3):787-98. PubMed ID: 17138841
[TBL] [Abstract][Full Text] [Related]
36. Insulin resistance directly contributes to androgenic potential within ovarian theca cells.
Qu J; Wang Y; Wu X; Gao L; Hou L; Erkkola R
Fertil Steril; 2009 May; 91(5 Suppl):1990-7. PubMed ID: 18672234
[TBL] [Abstract][Full Text] [Related]
37. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
[TBL] [Abstract][Full Text] [Related]
38. Insulin resistance in polycystic ovarian disease.
Bhatia V
South Med J; 2005 Sep; 98(9):903-10; quiz 911-2, 923. PubMed ID: 16217983
[TBL] [Abstract][Full Text] [Related]
39. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
40. Paracrine Regulation of Steroidogenesis in Theca Cells by Granulosa Cells Derived from Mouse Preantral Follicles.
Liu X; Qiao P; Jiang A; Jiang J; Han H; Wang L; Ren C
Biomed Res Int; 2015; 2015():925691. PubMed ID: 26357661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
